Archives of Toxicology

, Volume 85, Issue 10, pp 1209–1218 | Cite as

The association between bladder cancer and a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) gene

  • Mohammad Reza Safarinejad
  • Nayyer Shafiei
  • Shiva H. Safarinejad
Toxicogenomics

Abstract

Insulin-like growth factors (IGF) regulate growth and development and enhance cellular proliferation. IGF-binding protein-3 (IGFBP-3) inhibits IGF action by competitively binding IGFs that prevents their binding to the IGF cell surface receptor. Altered expression and serum levels of IGFBP-3 are associated with a number of malignancies. Study addressing the effect of IGFBP-3 gene polymorphism on bladder cancer is lacking. The aim of this study was to examine the effect of -202 A/C polymorphism of IGFBP-3 gene on development of bladder transitional cell carcinoma (TCC) and its correlation with serum concentration of IGF-1 and IGFBP-3 and with clinicopathological characteristics. One single nucleotide polymorphism (rs2854744) was genotyped by polymerase chain reaction–restriction fragment length polymorphism (PCR–RLFP) technique. One hundred and sixty-two bladder cancer patients were genotyped for this SNP. The genotypes were compared with those of a random sample of 324 age-matched controls of the general population. Serum levels of IGF-I and IGFBP-3 were also determined. We found statistically significant differences in the genotypic distribution between the cases and the control subject (χ2 = 6.43, df = 2.0, P = 0.028). Using CC genotype as a reference, the odds ratio for the subjects with AC genotype was 1.76 (95% CI: 1.27–2.84; P = 0.038). We detected a significantly decreased risk of bladder cancer associated with the AA genotype (adjusted OR = 0.48; 95% CI = 0.24–0.64; P = 0.001) compared with the CC genotype. This decreased risk was more pronounced for invasive bladder cancer. Age-adjusted mean serum IGFBP-3 levels were lowest in the individuals with the CC genotype. We found a positive correlation between age-adjusted serum IGFBP-3 levels and circulating IGF-1 concentrations (16% difference in IGFBP-3 in top vs. bottom tertiles of IGF-1, P for trend = 0.001), which was comparable across genotypes at the -202 IGFBP-3 locus (interaction term, F = 0.10, P = 0.87). Genetic polymorphism of the IGFBP-3 gene may be involved in the etiology of bladder TCC, and our results need further confirmation by larger studies.

Keywords

Insulin-like growth factor-binding protein 3 Polymorphism Urogenital cancer Bladder neoplasms Genetic variation 

References

  1. Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, Giles GG (2007) Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 16:763–768PubMedCrossRefGoogle Scholar
  2. Breslow NE, Day N (eds) (1980) Statistical methods in cancer research. The analysis of case-control studies. (IARC scientific publication no. 32), vol 1. International Agency for Research on Cancer, Lyon, FranceGoogle Scholar
  3. Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S et al (2006) Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 94:299–307PubMedCrossRefGoogle Scholar
  4. Chuang ST, Patton KT, Schafernak KT, Papavero V, Lin F, Baxter RC et al (2008) Over expression of insulin-like growth factor binding protein 3 in clear cell renal cell carcinoma. J Urol 179:445–449PubMedCrossRefGoogle Scholar
  5. Cubbage ML, Suwanichkul A, Powell DR (1990) Insulin-like growth factor binding protein-3. Organization of the human chromosomal gene and demonstration of promoter activity. J Biol Chem 265:12642–12649PubMedGoogle Scholar
  6. Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B et al (2001) Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86:1274–1280PubMedCrossRefGoogle Scholar
  7. Ehrenborg E, Larsson C, Stern I, Janson M, Powell DR, Luthman H (1992) Contiguous localization of the genes encoding human insulin-like growth factor binding proteins 1 (IGBP1) and 3 (IGBP3) on chromosome 7. Genomics 12:497–502PubMedCrossRefGoogle Scholar
  8. Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824–854PubMedCrossRefGoogle Scholar
  9. Franekova M, Halasova E, Bukovska E, Luptak J, Dobrota D (2008) Gene polymorphisms in bladder cancer. Urol Oncol 26:1–8PubMedCrossRefGoogle Scholar
  10. Genua M, Pandini G, Sisci D, Castoria G, Maggiolini M, Vigneri R et al (2009) Role of cyclic AMP response element-binding protein in insulin-like growth factor-i receptor up-regulation by sex steroids in prostate cancer cells. Caner Res 69:7270–7277CrossRefGoogle Scholar
  11. Guvakova MA (2007) Insulin-like growth factors control cell migration in health and disease. Int J Biochem Cell Biol 39:890–909PubMedCrossRefGoogle Scholar
  12. Hanafusa T, Yumoto Y, Nouso K, Nakatsukasa H, Onishi T, Fujikawa T et al (2002) Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 176:149–158PubMedCrossRefGoogle Scholar
  13. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J et al (1996) Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 98:2612–2615PubMedCrossRefGoogle Scholar
  14. Holmes MD, Pollak MN, Hankinson SE (2002) Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 11:862–867PubMedGoogle Scholar
  15. Jernström H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N et al (2001) Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 10:377–384PubMedGoogle Scholar
  16. Kiemeney LA (2008) Hereditary bladder cancer. Scand J Urol Nephrol Suppl 218:110–115PubMedCrossRefGoogle Scholar
  17. Kiemeney LA, Grotenhuis AJ, Vermeulen SH, Wu X (2009) Genome-wide association studies in bladder cancer: first results and potential relevance. Curr Opin Urol 19:540–546PubMedCrossRefGoogle Scholar
  18. Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, Thorleifsson G et al (2010) A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 42:415–419PubMedCrossRefGoogle Scholar
  19. Lin Y, Tamakoshi A, Kikuchi S, Yagyu K, Obata Y, Ishibashi T et al (2004) Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death. Int J Cancer 110:584–588PubMedCrossRefGoogle Scholar
  20. Metalli D, Lovat F, Tripodi F, Genua M, Xu SQ, Spinelli M et al (2010) The insulin-like growth factor receptor i promotes motility and invasion of bladder cancer cells through akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol 176:2997–3006PubMedCrossRefGoogle Scholar
  21. Miller SA, Dykes DD, Polesky HF (1998) A salting procedure for extracting DNA from nucleated cells. Nucleic Acid Res 16:1215CrossRefGoogle Scholar
  22. Moon JW, Chang YS, Ahn CW, Yoo KN, Shin JH, Kong JH et al (2006) Promoter -202 A/C polymorphism of insulin-like growth factor binding protein-3 gene and non-small cell lung cancer risk. Int J Cancer 118:353–356PubMedCrossRefGoogle Scholar
  23. Nissley P, Lopaczynski W (2002) Insulin-like growth factor receptors. Growth Factors 5:29–43CrossRefGoogle Scholar
  24. Nomura AM, Stemmermann GN, Lee J, Pollak MN (2003) Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men. Am J Epidemiol 158:424–431Google Scholar
  25. Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson J, Sigurdsson A et al (2009) Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 41:221–227PubMedCrossRefGoogle Scholar
  26. Ramachandran S, Liu P, Young AN, Yin-Goen Q, Lim SD, Laycock N et al (2005) Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene 24:188–198PubMedCrossRefGoogle Scholar
  27. Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353PubMedCrossRefGoogle Scholar
  28. Rochester MA, Patel N, Turney BW, Davies DR, Roberts IS, Crew J et al (2007) The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer. BJU Int 100:1396–1401PubMedCrossRefGoogle Scholar
  29. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X et al (2010) A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 42:978–984PubMedCrossRefGoogle Scholar
  30. Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6:1–12PubMedCrossRefGoogle Scholar
  31. Safarinejad MR (2011) Insulin-like growth factor binding protein-3 (IGFBP-3) gene variants are associated with renal cell carcinoma. BJU Int. doi:10.1111/j.1464-410X.2010.10017.x
  32. Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN (2003) Polymorphic variation at the 2202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer 107:60–64PubMedCrossRefGoogle Scholar
  33. Serrano ML, Sánchez-Gómez M, Bravo MM (2010) Cervical scrapes levels of insulin-like growth factor-II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer. Horm Metab Res 42:977–981Google Scholar
  34. Sobin LH, Wittekind Ch (1997) TNM classification of malignant tumours, 5th edn. Wiley-Liss, New YorkGoogle Scholar
  35. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH et al (2000) Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92:1910–1917PubMedCrossRefGoogle Scholar
  36. Sternberg CN, Calabro F (2000) Chemotherapy and management of bladder tumours. BJU Int 85:599–610PubMedCrossRefGoogle Scholar
  37. Sugumar A, Liu YC, Xia Q, Koh YS, Matsuo K (2004) Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature. Int J Cancer 111:293–297PubMedCrossRefGoogle Scholar
  38. Sun G, Chagnon M, Bouchard C (2000) A common polymorphism in the human insulin-like growth factor binding protein 3 gene. Mol Cell Probes 14:55–56PubMedCrossRefGoogle Scholar
  39. Torrisi R, Mezzetti M, Johansson H, Barreca A, Pigatto F, Robertson C et al (2000) Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial. Int J Cancer 87:601–605PubMedCrossRefGoogle Scholar
  40. Wang L, Habuchi T, Tsuchiya N, Mitsumori K, Ohyama C, Sato K et al (2003) Insulin-like growth factor-binding protein-3 gene 2202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res 63:4407–4411PubMedGoogle Scholar
  41. Watson JA, Burling K, Fitzpatrick P, Kay E, Kelly J, Fitzpatrick JM et al (2009) Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder. BJU Int 103:694–697PubMedCrossRefGoogle Scholar
  42. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X (1999) Plasma levels of insulin-like growth factor-I and lung cancer risk: a case control analysis. J Natl Cancer Inst 91:151–156PubMedCrossRefGoogle Scholar
  43. Zhao H, Grossman HB, Spitz MR, Lerner SP, Zhang K, Wu X (2003) Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol 169:714–717PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Mohammad Reza Safarinejad
    • 1
  • Nayyer Shafiei
    • 1
  • Shiva H. Safarinejad
    • 1
  1. 1.Private Practice of Urology and AndrologyTehranIran

Personalised recommendations